Previous studies have shown that normalized PTPN22 expression in vitro significantly correlates with the clinical outcomes of targeted therapies for RA, and circPTPN22 has potential as a diagnostic biomarker for RA (31, 32). Here, PTPN22 is linked to rheumatoid arthritis.